Nanotechnology has an increasingly large impact on a broad scope of biotechnological, pharmacological and pure technological applications. Its current use in bioenergy production from biomass is very restricted. The present study is based on the utilization of nanoparticles as an additive to feed bacteria that break down natural substances. The novel notion of dosing ions using modified nanoparticles can be used to progress up biogas production in oxygen free digestion processes. While minute nanoparticles are unstable, they can be designed to provide ions in a controlled approach, so that the maximum enhancement of biogas production that has been reported can be obtained. Nanoparticles are dissolved in a programmed way in an anaerobic atmosphere and are supplied in a sustainable manner to microbiotic organisms responsible for the degradation of organic material, which is a role that fits them well. Therefore, biogas fabrication can be increased up to 200%, thereby increasing the degradation of organic waste.

Background: Type 2 diabetes mellitus (DM2) is a chronic and sometimes fatal condition which affects people all over the world. Nanotherapeutics have shown tremendous potential to combat chronic diseases—including DM2—as they enhance the overall impact of drugs on biological systems. Greenly synthesized silver nanoparticles (AgNPs) from Catharanthus roseus methanolic extract (C. AgNPs) were examined primarily for their cytotoxic and antidiabetic effects. Methods: Characterization of C. AgNPs was performed by UV–vis spectroscopy, Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and atomic force microscopy (AFM). The C. AgNPs were trialed on Vero cell line and afterwards on an animal model (rats). Results: The C. AgNPs showed standard structural and functional characterization as revealed by FTIR and XRD analyses. The zetapotential analysis indicated stability while EDX analysis confirmed the formation of composite capping with Ag metal. The cytotoxic effect (IC50) of C. AgNPs on Vero cell lines was found to be 568 g/mL. The animal model analyses further revealed a significant difference in water intake, food intake, body weight, urine volume, and urine sugar of tested rats after treatment with aqueous extract of C. AgNPs. Moreover, five groups of rats including control and diabetic groups (NC1, PC2, DG1, DG2, and DG3) were investigated for their blood glucose and glycemic control analysis. Conclusions: The C. AgNPs exhibited positive potential on the Vero cell line as well as on experimental rats. The lipid profile in all the diabetic groups (DG1-3) were significantly increased compared with both of the control groups (p < 0.05). The present study revealed the significance of C. AgNPs in nanotherapeutics.